Online inquiry

IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11410MR)

This product GTTS-WQ11410MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDGFRA gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001347829.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5156
UniProt ID P16234
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11410MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5677MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ5620MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDP791
GTTS-WQ4956MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA c2G4-N
GTTS-WQ10886MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ11453MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ7909MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ4576MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986004
GTTS-WQ12086MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MOR-03087
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.